Ridgeline Therapeutics
Organisation
People
Executive director, r&d, 17 Sept 2026, reporter.nih.gov
Senior scientist, 23 Aug 2023, reporter.nih.gov
Grants and prizes
Cardiovascular Safety and Scalable Manufacturing for Investigational New Drug Filing of a Novel Oral Drug to Accelerate Musculoskeletal Recovery in Older Adults, R44AG102216, US$2.1m, 17 Sept 2026, reporter.nih.gov
R44, Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults, R44AG092210, US$904.8k, 2025–2027, 28 Jul 2026, reporter.nih.gov
U44, Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture, U44AG074107, US$236.5k, 2021–2025, 25 Jun 2024, reporter.nih.gov
R43, A Novel Small Molecule Oral Therapeutic to Prevent and Reverse Skeletal Muscle Atrophy in Aging Adults, R43AG084460, US$322.4k, 2023–2025, 23 Aug 2023, reporter.nih.gov